GlassScriptPhysician profile
Rodger David Macarthur
NPI 1831137959
$150,354.25
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115K · 2020: $27K · 2021: $3,829 · 2022: $3,899 · 2023: $341 · 2024: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Products, LP | $77,298.23 | 2019-2022 | |
| Viiv Healthcare Company | $69,822.24 | 2019-2024 | Dovato |
| Glaxosmithkline, LLC. | $1,163.26 | 2019 | |
| Gilead Sciences, INC. | $846.16 | 2019-2024 | Biktarvy |
| Janssen Scientific Affairs, LLC | $272.76 | 2019 | |
| Janssen Biotech, INC. | $265.80 | 2019-2022 | |
| Allergan, INC. | $252.60 | 2019 | |
| Merck Sharp & Dohme LLC | $130.53 | 2019-2024 | Delstrigo, Dificid, Pifeltro |
| Angiodynamics, INC. | $104.14 | 2019 | |
| Next Science LLC | $96.97 | 2022 | |
| Abbvie INC. | $56.33 | 2021-2023 | |
| Melinta Therapeutics, LLC | $45.23 | 2022-2023 | Kimyrsa, Vabomere |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodger Macarthur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.